ArticleHealth science reports2026
Neutrophil-to-Albumin Ratio Mediates the Association Between Life's Crucial 9 and Sarcopenia: A Cross-Sectional Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutrophil-to-Albumin Ratio Mediates the Association Between Life's Crucial 9 and Sarcopenia: A Cross-Sectional Study.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emerging evidence links cardiovascular health, inflammation, and sarcopenia (SP), but the mediating mechanisms remain unclear. Life's Crucial 9 (LC9), a novel metric integrating mental health with cardiovascular risk factors, and neutrophil-to-albumin ratio (NPAR), a cost-effective inflammatory biomarker, may jointly influence SP risk. This investigation seeks to examine the connection between LC9 and sarcopenia, assessing whether NPAR acts as a mediator in this relationship. Methods: Multivariable logistic regression, smooth curve fitting, subgroup analysis, and other methods were employed to investigate the relationship between LC9 and the incidence of SP. Additionally, mediation analysis was conducted to examine the potential relationship between NPAR levels, LC9, and SP. Results: This analysis involved 7,761 participants, of whom 648 reported experiencing SP events. After adjusting for all covariates using multivariable logistic regression, a 10-point increase in LC9 was associated with a 37% reduction in the prevalence of sarcopenia (OR = 0.63, 95% CI: 0.59, 0.67). Additionally, sarcopenia increased by 1.17-fold for each unit increase in NPAR (OR = 1.17, 95% CI: 1.11, 1.24). Conversely, the NPAR level and the highest quantile of SP prevalence increased by 2.26 times, respectively ( Conclusion: LC9 inversely correlates with SP, partially mediated by NPAR-driven inflammation, suggesting anti-inflammatory interventions may mitigate SP risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.